Investors & Media

Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic immune modulation.

Cue Biopharma’s off-the-shelf biologics are engineered to mimic the natural signals, or “Cues,” of the immune system to address the specificity and diversity of the human immune system and activate only the relevant T-cells. Immuno-STATs have the potential to provide the patient with a more effective response while preserving safety, by avoiding the systemic and indiscriminate immune activation of available immune-modulating drugs that can often lead to severe adverse events, dose-limiting toxicities, treatment discontinuation, and inadequate efficacy.

Headquartered in Boston, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

Investor Overview Presentation

April 2024


Investor Kit

Recent News

Learn how Immuno-STAT Biologics selectively modulate disease-associated T cells to fight cancer.
 Play Video